Genzyme to gain prenatal genetic testing risk assessment service via Genetrix buy.
This article was originally published in The Gray Sheet
Executive Summary
GENZYME GAINING PRENATAL GENETIC RISK ASSESSMENT PROGRAM VIA GENETRIX acquisition. On Feb. 14, Genzyme announced that it had signed agreement to acquire the privately held Phoenix-based genetic testing company in a stock swap valued at $36.7 mil. In addition to providing genetic testing for cancer monitoring, Genetrix offers a genetic risk assessment service designed to oversee the utilization of prenatal testing for managed care networks in exchange for a capitated fee. Genetrix set up the managed care program a year ago and expects to sign a contract with its first customer, a third-party administrator in Maryland, by the beginning of March.